Neuropace Inc
NASDAQ:NPCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.1), the stock would be worth $12.3 (27% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.6 | $16.8 |
0%
|
| 3-Year Average | 4.1 | $12.3 |
-27%
|
| 5-Year Average | 4 | $11.97 |
-29%
|
| Industry Average | 1.7 | $5.2 |
-69%
|
| Country Average | 2.4 | $7.25 |
-57%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$490.2m
|
/ |
Jan 2026
$100m
|
= |
|
|
$490.2m
|
/ |
Dec 2026
$100.9m
|
= |
|
|
$490.2m
|
/ |
Dec 2027
$125.6m
|
= |
|
|
$490.2m
|
/ |
Dec 2028
$156.7m
|
= |
|
|
$490.2m
|
/ |
Dec 2029
$178.9m
|
= |
|
|
$490.2m
|
/ |
Dec 2030
$202.7m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Neuropace Inc
NASDAQ:NPCE
|
564.1m USD | 5.6 | -26.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 17 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3.5 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 3 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 4.5 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 1.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 7.8 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 10.5 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 2 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.9 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Neuropace Inc
Glance View
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
